Orexo Interim Report Q4 2023, incl. Full Year Report

Important events after the end of the ­period Important events after the end of the ­period   Financial outlook 2024 The financial outlook 2024 is based on a forward looking assumption of a USD/SEK exchange rate of 10.28 calculated as an average ofDecember 2023by the Riksbanken. Strong recovery in financial results and FDA initiated the review of OX124  CEO Comments in brief "I am pleased to report a Q4 result delivering a positive EBITDA and strong Zubsolv ®net...

Important events after the end of the ­period

 

Financial outlook 2024

The financial outlook 2024 is based on a forward looking assumption of a USD/SEK exchange rate of 10.28 calculated
as an average of December 2023 by the Riksbanken.

Strong recovery in financial results and FDA initiated the review of OX124 

CEO Comments in brief

"I am pleased to report a Q4 result delivering a positive EBITDA and strong Zubsolv^® net sales both compared to Q4 2022 and Q3 2023. Zubsolv net sales year over year grew more than 6 percent in both SEK and USD, and nearly 8 percent quarter over quarter. I am also delighted to share that we are continuing to drive efficiencies across the business and have reduced operating expenses by 23 percent from last year. This recovery in financial performance is not driven by exchange rates, on the contrary, our EBITDA in H2 would have been nearly SEK 8 million higher if we had applied the exchange rates from end of 2022. 

I am also pleased to announce that we, despite currency headwinds, reached our financial guidance for 2023, and in particular the positive EBITDA for H2. With relatively stable exchange rates and no other extraordinary events in 2024, we are confident we can reach a positive EBITDA for the FY 2024."

To read the full CEO Comments view attached PDF.

Contact persons quarterly report
Nikolaj Sørensen, President and CEO, Fredrik Järrsten, EVP and CFO, or Lena Wange, IR & Communications Director
Tel: +46 18 780 88 00, +1 855 982 7658, E-mail: ir@orexo.com.

Presentation
On Feb. 8, at 2 pm CET analysts, investors and ­media are invited to attend a presentation, incl. a Q&A. 

To attend via teleconference where you can ask questions verbally: 
https://conference.financialhearings.com/teleconference/?id=2001504

When registered you will be provided ­phone ­numbers and a conference ID to access the ­conference.

To attend via webcast:
https://ir.financialhearings.com/orexo-q4-2023

Prior to the call, presentation material will be ­available on the website under Investors/Reports/Audiocasts.

This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above at 8 am CET on February 8, 2024.

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/orexo-interim-report-q4-2023-incl-full-year-report-302057222.html